GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2Results posted

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

338

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 30-50

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04881760

Org study ID18122

Secondary IDJ1I-MC-GZBFEli Lilly and Company

Timeline

Milestones

Study first posted2021-05-11actual

Study start2021-05-20actual

Primary completion2022-05-16actual

Study completion2022-11-22actual

Last update posted2023-09-13actual

Results first posted2023-09-13actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and <30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease

•Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

Exclusion criteria

•Participants must not have type 1 or type 2 diabetes mellitus

•Participants must not have had an increase or decrease in body weight > more than 5 kg (11 pounds) within the past 3 months

•Participants must not have had surgery for obesity or plan to have such surgery during the study

•Participants must not be using medications that promote weight loss or cause weight gain

•Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)

•Participants must not have used marijuana within the last 3 months.

•Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months

•Participants must not have active cancer within the last 5 years

•Participants must not have uncontrolled high blood pressure

•Participants must not have liver disease other than non-alcoholic fatty liver disease

•Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2

•Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection

•Participants must not have a major problem with depression or other mental illness within the last 2 years

•Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)

•Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)

Endpoints (28)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

28 endpoints

Primary/registry result

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 24

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	-1.55	—
1 mg LY3437943	-7.18	—
4 mg LY3437943 (2 mg)	-12.00	—
4 mg LY3437943	-13.80	—
8 mg LY3437943 (2 mg)	-16.64	—
8 mg LY3437943 (4 mg)	-18.26	—
12 mg LY3437943 (2 mg)	-17.39	—

LS Mean difference (Final Values)-5.6495% CI-7.34 – -3.94p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-10.4595% CI-12.21 – -8.70p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-12.2595% CI-14.42 – -10.08p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-15.1095% CI-16.90 – -13.30p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-16.7295% CI-18.86 – -14.58p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-15.8595% CI-17.57 – -14.13p<0.001Mixed Models Analysis

Primary/protocol endpoint

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 24

Body weight, % change

percent change from baseline, improvement

Secondary/registry result

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	-2.11	—
1 mg LY3437943	-8.67	—
4 mg LY3437943 (2 mg)	-16.32	—
4 mg LY3437943	-17.83	—
8 mg LY3437943 (2 mg)	-21.72	—
8 mg LY3437943 (4 mg)	-23.88	—
12 mg LY3437943 (2 mg)	-24.22	—

LS Mean difference (Final Values)-6.5795% CI-8.94 – -4.20p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-14.2195% CI-17.64 – -10.78p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-15.7295% CI-19.05 – -12.40p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-19.6295% CI-22.73 – -16.51p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-21.7895% CI-25.05 – -18.51p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-22.1195% CI-24.92 – -19.31p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction

Time frame:Week 24

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	26	—
1 mg LY3437943	59	—
4 mg LY3437943 (2 mg)	87	—
4 mg LY3437943	94	—
8 mg LY3437943 (2 mg)	100	—
8 mg LY3437943 (4 mg)	100	—
12 mg LY3437943 (2 mg)	97	—

Risk Difference (RD)3395% CI17 – 49p<0.001Regression, Logistic

Risk Difference (RD)6195% CI45 – 77p<0.001Regression, Logistic

Risk Difference (RD)6895% CI54 – 81p<0.001Regression, Logistic

Risk Difference (RD)7495% CI63 – 85p<0.001Regression, Logistic

Risk Difference (RD)7195% CI59 – 82p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction

Time frame:Week 48

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	27	—
1 mg LY3437943	64	—
4 mg LY3437943 (2 mg)	87	—
4 mg LY3437943	97	—
8 mg LY3437943 (2 mg)	100	—
8 mg LY3437943 (4 mg)	100	—
12 mg LY3437943 (2 mg)	100	—

Risk Difference (RD)3795% CI20 – 54p<0.001Regression, Logistic

Risk Difference (RD)6095% CI44 – 76p<0.001Regression, Logistic

Risk Difference (RD)7095% CI57 – 83p<0.001Regression, Logistic

Risk Difference (RD)7395% CI62 – 84p<0.001Regression, Logistic

Risk Difference (RD)7395% CI67 – 84p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction

Time frame:Week 24

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	3	—
1 mg LY3437943	25	—
4 mg LY3437943 (2 mg)	59	—
4 mg LY3437943	72	—
8 mg LY3437943 (2 mg)	83	—
8 mg LY3437943 (4 mg)	94	—
12 mg LY3437943 (2 mg)	90	—

Risk Difference (RD)2295% CI11 – 33p<0.001Regression, Logistic

Risk Difference (RD)5695% CI38 – 73p<0.001Regression, Logistic

Risk Difference (RD)6995% CI53 – 85p<0.001Regression, Logistic

Risk Difference (RD)8095% CI66 – 93p<0.001Regression, Logistic

Risk Difference (RD)9195% CI83 – 100p<0.001Regression, Logistic

Risk Difference (RD)8795% CI78 – 96p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction

Time frame:Week 48

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	9	—
1 mg LY3437943	27	—
4 mg LY3437943 (2 mg)	73	—
4 mg LY3437943	76	—
8 mg LY3437943 (2 mg)	90	—
8 mg LY3437943 (4 mg)	91	—
12 mg LY3437943 (2 mg)	93	—

Risk Difference (RD)1895% CI5 – 31p0.008Regression, Logistic

Risk Difference (RD)6495% CI48 – 81p<0.001Regression, Logistic

Risk Difference (RD)6795% CI51 – 84p<0.001Regression, Logistic

Risk Difference (RD)8195% CI69 – 94p<0.001Regression, Logistic

Risk Difference (RD)8295% CI71 – 94p<0.001Regression, Logistic

Risk Difference (RD)8495% CI74 – 94p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction

Time frame:Week 24

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	1	—
1 mg LY3437943	10	—
4 mg LY3437943 (2 mg)	29	—
4 mg LY3437943	44	—
8 mg LY3437943 (2 mg)	51	—
8 mg LY3437943 (4 mg)	68	—
12 mg LY3437943 (2 mg)	70	—

Risk Difference (RD)995% CI1 – 17p0.029Regression, Logistic

Risk Difference (RD)2795% CI11 – 43p<0.001Regression, Logistic

Risk Difference (RD)4395% CI26 – 60p<0.001Regression, Logistic

Risk Difference (RD)4995% CI33 – 66p<0.001Regression, Logistic

Risk Difference (RD)6795% CI51 – 83p<0.001Regression, Logistic

Risk Difference (RD)6895% CI56 – 80p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction

Time frame:Week 48

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	2	—
1 mg LY3437943	16	—
4 mg LY3437943 (2 mg)	55	—
4 mg LY3437943	64	—
8 mg LY3437943 (2 mg)	73	—
8 mg LY3437943 (4 mg)	77	—
12 mg LY3437943 (2 mg)	83	—

Risk Difference (RD)1595% CI6 – 24p0.002Regression, Logistic

Risk Difference (RD)5395% CI36 – 70p<0.001Regression, Logistic

Risk Difference (RD)6395% CI47 – 79p<0.001Regression, Logistic

Risk Difference (RD)7195% CI55 – 87p<0.001Regression, Logistic

Risk Difference (RD)7595% CI62 – 89p<0.001Regression, Logistic

Risk Difference (RD)8295% CI71 – 92p<0.001Regression, Logistic

Secondary/registry result

Mean Change From Baseline in Body Weight

Time frame:Baseline, Week 24

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
Placebo	-1.27	—
1 mg LY3437943	-7.72	—
4 mg LY3437943 (2 mg)	-12.59	—
4 mg LY3437943	-14.79	—
8 mg LY3437943 (2 mg)	-17.70	—
8 mg LY3437943 (4 mg)	-19.75	—
12 mg LY3437943 (2 mg)	-18.53	—

LS Mean difference (Final Values)-6.4695% CI-8.36 – -4.56p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.3295% CI-13.34 – -9.30p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-13.5295% CI-15.99 – -11.05p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-16.4395% CI-18.41 – -14.45p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-18.4895% CI-20.93 – -16.04p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-17.2695% CI-19.11 – -15.40p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg	95% CI
Placebo	-1.84	—
1 mg LY3437943	-9.37	—
4 mg LY3437943 (2 mg)	-17.32	—
4 mg LY3437943	-19.13	—
8 mg LY3437943 (2 mg)	-23.52	—
8 mg LY3437943 (4 mg)	-25.88	—
12 mg LY3437943 (2 mg)	-26.17	—

LS Mean difference (Final Values)-7.5395% CI-10.18 – -4.88p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-15.4895% CI-19.35 – -11.60p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-17.2995% CI-21.19 – -13.39p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-21.6995% CI-25.25 – -18.12p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-24.0495% CI-27.72 – -20.36p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-24.3495% CI-27.40 – -21.27p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in BMI

Time frame:Baseline, Week 24

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg/m^2	95% CI
Placebo	-0.49	—
1 mg LY3437943	-2.64	—
4 mg LY3437943 (2 mg)	-4.47	—
4 mg LY3437943	-5.13	—
8 mg LY3437943 (2 mg)	-6.15	—
8 mg LY3437943 (4 mg)	-6.84	—
12 mg LY3437943 (2 mg)	-6.44	—

LS Mean difference (Final Values)-2.1595% CI-2.80 – -1.50p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-3.9895% CI-4.66 – -3.29p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-4.6495% CI-5.46 – -3.82p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-5.6695% CI-6.34 – -4.99p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-6.3595% CI-7.17 – -5.53p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-5.9595% CI-6.59 – -5.32p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in BMI

Time frame:Baseline, Week 48

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg/m^2	95% CI
Placebo	-0.72	—
1 mg LY3437943	-3.22	—
4 mg LY3437943 (2 mg)	-6.14	—
4 mg LY3437943	-6.67	—
8 mg LY3437943 (2 mg)	-8.12	—
8 mg LY3437943 (4 mg)	-9.02	—
12 mg LY3437943 (2 mg)	-9.14	—

LS Mean difference (Final Values)-2.5095% CI-3.42 – -1.57p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-5.4295% CI-6.81 – -4.03p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-5.9595% CI-7.23 – -4.67p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-7.4095% CI-8.62 – -6.18p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-8.3095% CI-9.55 – -7.05p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-8.4295% CI-9.49 – -7.35p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Waist Circumference

Time frame:Baseline, Week 24

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), centimeters (cm)	95% CI
Placebo	-2.60	—
1 mg LY3437943	-5.43	—
4 mg LY3437943 (2 mg)	-10.33	—
4 mg LY3437943	-12.55	—
8 mg LY3437943 (2 mg)	-13.74	—
8 mg LY3437943 (4 mg)	-14.99	—
12 mg LY3437943 (2 mg)	-14.33	—

LS Mean difference (Final Values)-2.8295% CI-5.23 – -0.41p0.022Mixed Models Analysis

LS Mean difference (Final Values)-7.7395% CI-10.32 – -5.13p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-9.9595% CI-12.47 – -7.43p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.1495% CI-13.72 – -8.56p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-12.3895% CI-14.87 – -9.90p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-11.7395% CI-14.04 – -9.43p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Waist Circumference

Time frame:Baseline, Week 48

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), cm	95% CI
Placebo	-2.64	—
1 mg LY3437943	-6.49	—
4 mg LY3437943 (2 mg)	-14.58	—
4 mg LY3437943	-14.87	—
8 mg LY3437943 (2 mg)	-18.53	—
8 mg LY3437943 (4 mg)	-18.50	—
12 mg LY3437943 (2 mg)	-19.60	—

LS Mean difference (Final Values)-3.8495% CI-6.77 – -0.91p0.010Mixed Models Analysis

LS Mean difference (Final Values)-11.9495% CI-15.54 – -8.33p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-12.2295% CI-16.11 – -8.33p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-15.8895% CI-19.33 – -12.43p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-15.8595% CI-19.39 – -12.31p<0.001Mixed Models Analysis

LS Mean difference (Final Values)-16.9595% CI-20.13 – -13.78p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction

Time frame:Week 24

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction

Time frame:Week 48

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction

Time frame:Week 24

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction

Time frame:Week 48

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction

Time frame:Week 24

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction

Time frame:Week 48

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Body Weight

Time frame:Baseline, Week 24

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in BMI

Time frame:Baseline, Week 24

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in BMI

Time frame:Baseline, Week 48

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Waist Circumference

Time frame:Baseline, Week 24

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Waist Circumference

Time frame:Baseline, Week 48

Waist circumference, change

change from baseline, improvement

Publications (5)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Development of the Weight and Emotions Scale (WES).
Obesity science & practice2026 Feb (month)PMID41589220doi:10.1002/osp4.70119via pubmed nct search
Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.
Advances in therapy2026 Jan (month)PMID41201783doi:10.1007/s12325-025-03386-2via pubmed nct search
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Obesity pillars2025 Dec (month)PMID41216380doi:10.1016/j.obpill.2025.100220via pubmed nct search
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nature medicine2024 Jul (month)PMID38858523doi:10.1038/s41591-024-03018-2via clinicaltrials gov reference derived + pubmed nct search
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine2023 Aug 10PMID37366315doi:10.1056/NEJMoa2301972via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.